Advancing a class on top of statins
World Class Leadership
Management Team
Steve Gullans Chief Executive Officer
Mina Sooch


Dr. Gullans has broad experience across the life sciences industry including being a board director at Gemphire since 2016, prior to joining full-time 2018. Previously Dr. Gullans was Managing Director at Excel Venture Management, a Boston-based life sciences venture capital firm which he cofounded in 2008. At Excel he spearheaded many successful investments in a variety of therapeutics and diagnostics companies, including Cleveland HeartLab. Prior to Excel, Dr. Gullans was co-founder and CEO of RxGen, Inc. and Chief Scientific Officer at U.S. Genomics. Currently Dr. Gullans is a director and co-founder of Orionis Biosciences LLC, a biotech therapeutics company and a director of N-of-One Inc., an oncology diagnostics entity. He advises on innovation at the Cleveland Clinic and Partners HealthCare.

For nearly 20 years, Dr. Gullans was a faculty member at Harvard Medical School and Brigham and Women’s Hospital where he published more 130 research papers in many fields. Dr. Gullans is passionate about innovation and co-authored two books with Juan Enriquez, including “Evolving Ourselves,” a book that provides a sweeping tour of how humans are changing the course of evolution. Dr. Gullans has spoken globally including at TEDMED and TEDx. He received his Ph.D. from Duke University, post-doctoral training at Yale University, and his B.S. from Union College. He is an elected Fellow of the American Heart Association as well as the American Association for the Advancement of Science.

Jeff Mathiesen Chief Financial Officer
Jeff Mathiesen


Jeff Mathiesen serves as our Chief Financial Officer. Prior to joining Gemphire Therapeutics, he served as CFO of Sunshine Heart, Inc., leading the medical device company through its transition from the Australian capital markets to the U.S., which included a successful IPO and equity financings totaling approximately $100 million. Mr. Mathiesen has more than 20 years of experience as Chief Financial Officer (CFO) of publicly traded companies, including two successful initial public offerings (IPOs). His experience encompasses a variety of highly competitive, technology based industries in organizations with global reach and includes several M&A transactions, divestitures, organizational development and equity and debt financing. He began his career at Deloitte. Mr. Mathiesen also serves as Director and Audit Committee Chair of Sun BioPharma, Inc. a publicly traded biopharmaceutical company developing therapies for pancreatic diseases. Mr. Mathiesen graduated summa cum laude from the University of South Dakota with a B.S. degree in Accounting.

Charles Bisgaier Chief Scientific Officer and Co-Founder
Charles Bisgaier


Dr. Bisgaier serves as our Chairman and Chief Scientific Officer. From 1990 to 1998, Dr. Bisgaier was an Associate Research Fellow in the Department of Vascular and Cardiac Disease at Warner-Lambert/Parke-Davis. There he participated in the discovery and/or development of gemfibrozil (LOPID®), atorvastatin (LIPITOR®) and gemcabene (AKA CI-1027 and PD 72953). Subsequently, Dr. Bisgaier co-founded the first Esperion Therapeutics (1998- 2004), which was then acquired by Pfizer. At Pfizer he then served as the Senior Director of Pharmacology at the Esperion Division of Pfizer Global Research and Development. Notably, he was a major influence in the discovery, research and/or development of many small molecules with potential utility for metabolic syndrome including ETC-1002 (AKA ESP 55016) which was licensed by the new Esperion (NASDAQ: ESPR) from Pfizer, as well as HDL-therapy product candidates, such as ApoA-I Milano (ETC-216) which was also licensed by The Medicines Company (NASDAQ: MDCO) from Pfizer. After Pfizer, he served as a Company Director, Board Member and President of Pipex Pharmaceuticals (2006-2008, currently known as Synthetic Biologics, NYSE: SYN), a specialty pharmaceutical company focused on developing fibrotic and neurological disease therapies, that included a treatment for Relapsing Remitting Multiple Sclerosis. Both Pipex Pharmaceuticals and the first Esperion Therapeutics became public companies through a reverse-merger and an initial public offering (IPO), respectively during Dr. Bisgaier's tenure. He is also a co-founder of Michigan Life Therapeutics (predecessor to Gemphire) and Michigan Life Ventures. In addition, he is currently a Board member at Hygieia, Inc., a company that has developed a novel handheld medical device to assist diabetics to determine appropriate dosage when self-administering insulin, and a Board member at BioSavita Inc., a company that has developed a novel platform technology for protein expression in yeast. He also has served as a Board member (2009-2014) and President and CEO (2010-2011) of ProNAi Therapeutics (NASDAQ: DNAI). Currently, Dr. Bisgaier is also an Adjunct Associate Professor of Pharmacology at the University of Michigan. He received a B.A. in Biology from the State University College at Oneonta, NY (1974), and a M.S.(1977) and Ph.D. (1981) in biochemistry from George Washington University, Washington, D.C. After receiving his doctorate, he studied lipoprotein metabolism within the Specialized Center of Research (SCOR) for atherosclerosis at Columbia University College of Physicians and Surgeons, NY.

Lee Golden Chief Medical Officer
Lee Golden


Dr. Golden has over 20 years of clinical and industry experience. He has held several roles with increasing responsibilities within the pharmaceutical industry since beginning his career with Pfizer, Inc. His experience includes Medical Affairs, Clinical Development and Business Development, for market leading therapeutics within primary care and orphan indications. At Pfizer, in addition to working on the Global atherosclerosis team and overseeing several large global cardiovascular trials, he was the US Medical Team Leader during the filing and launch of several products. After leaving Pfizer, Dr. Golden broadened his experience with responsibility for leading medical teams in Cardiopulmonary, GI and CNS therapeutic areas. During his time at Actelion he oversaw multiple products and trials in Pulmonary Arterial Hypertension and was involved with design and oversight of several other pulmonary related diseases. In his previous role at Eisai Inc. he was the Therapeutic Area Head for Cardiovascular and Blood Disorders where he was responsible for leading global development teams from discovery through NDA/MAA approvals.

Dr. Golden was most recently the Therapeutic Area Head for CV, Pulmonary and CNS at Mesoblast, Ltd., a global regenerative medicine company. His was responsible for overseeing the strategic planning, implementation and execution from preclinical through registration across multiple indications. He championed regulatory interactions that led to the first global phase 3 cardiovascular program with allogeneic stem cells in patients with congestive heart failure.

Dr. Golden earned his MD degree from New York University School of Medicine. After his Internal Medicine Residency at New York University Medical Center, he completed fellowships in Cardiology, At University of Miami Health Center, and Interventional Cardiology, at George Washington University Hospital. While at George Washington University Hospital, Dr. Golden also held the position of Adjunct Instructor.

Seth Reno Chief Commercial Officer
David Lowenschuss


Mr. Reno serves as our Chief Commercial Officer and has over 25 years of experience in the Bio-Pharmaceutical industry. He has extensive experience in building commercial capabilities to successfully commercialize both small and large molecules across a range of therapeutic areas including the cardiovascular market. Prior to joining Gemphire, he spent five years at Medimmune building commercial teams and capabilities that focused on launching complex biologics such as Mylept and Lynparza with orphan designation status into rare disease markets. As Medimmune’s Head of Commercial Operations he was responsible for leading core business functions across: Sales Operations, Marketing Operations, Market Research, Fleet Services, Sales Training, Commercial Insight, Advanced Analytics and Forecasting. Mr. Reno spent ten years at AstraZenca across a number of roles in Sales, Commercial Operations, Managed Markets and Brand Team. He led the Commercial Insight’s team for the dyslipidemia franchise, most notably the successful launch of Crestor’s atherosclerosis indication. He also led the insight work for several mixed dyslipidemia fixed dose combinations in development with industry partners. Prior to Joining AstraZeneca in 2001, Mr. Reno Spent eleven years at Wyeth in commercial operations and sales account management successfully building B2B relationships across Federal, Trade, Military and Commercial accounts. Mr. Reno holds a B.S. in Human Resources from University of Delaware and a MBA from Strayer University.